Lincoln Park Backs Publicly Traded Zalicus

Zalicus Inc., a publicly traded biopharmaceutical company, announced that it has entered into a stock purchase agreement with Lincoln Park Capital Fund. Under the terms of the deal, Zalicus has the right to sell up to $25 million in shares of its common stock to Lincoln Park.

DealsNorth AmericaUSBriefs